hypothyroidism

in review 3 min read Updated 2026-11-19
hypothyroidism

Do not screen asymptomatic adults (CTFPHC 2019). Start levothyroxine 1.6 µg/kg/day in young healthy adults with overt primary hypothyroidism, or 25–50 µg/day in older adults / CAD, rechecking TSH in 4–6 weeks. In subclinical hypothyroidism, treat if TSH >10 mU/L, pregnancy/planning, or selected symptomatic younger adults — not routinely in adults ≥65 (TRUST (2017)). Always exclude adrenal insufficiency before starting LT4 in suspected central hypothyroidism.


screening and diagnosis

  • CTFPHC 2019: strong recommendation against routine TSH screening in asymptomatic non-pregnant adults ≥18. Does not apply to patients with prior thyroid disease/surgery, neck radiation, RAI, pituitary disease, or thyroid-active drugs (lithium, amiodarone, immune checkpoint inhibitors).
  • Primary vs central:
    • Primary overt: elevated TSH + low free T4 (Hashimoto thyroiditis is the commonest cause in iodine-replete regions; routine anti-TPO testing is unnecessary once overt hypothyroidism is diagnosed).
    • Central (secondary/tertiary): low free T4 with low or inappropriately normal TSH → never rely on TSH to diagnose or titrate central disease; evaluate the remaining pituitary axes (especially morning cortisol) and order pituitary MRI → pituitary disorders.
  • Non-thyroidal illness syndrome (euthyroid sick): avoid testing TSH/T4 in acutely ill hospitalised patients unless true thyroid disease is strongly suspected (typically low T3, normal/low T4, normal/low TSH; recovers without LT4 — ATA 2014 recommends against treatment).

levothyroxine initiation and titration

Levothyroxine (LT4) monotherapy is standard of care (ATA 2014 recommends against routine LT4/LT3 combination, LT3 monotherapy, desiccated thyroid extract, or compounded thyroid hormones).

clinical scenariostarting LT4 dosemonitoring & target
young, healthy, overt primary1.6 µg/kg/day (full replacement)recheck TSH in 4–6 weeks; target normal reference range
elderly (>65 y), frail, or CAD/arrhythmia25–50 µg/day (or 12.5–25 µg if severe CAD); titrate by 12.5–25 µg q4–6 weeksavoids precipitating angina or AF; target upper half of normal TSH (e.g. 4–6 mU/L) in frail older adults
central hypothyroidismweight-based (start low if older/CAD) AFTER excluding/treating AItitrate by free T4 (upper half of normal range), never TSH
pregnancyincrease pre-pregnancy dose by ~25–30% at positive testsee thyroid disease in pregnancy
exclude adrenal insufficiency before starting levothyroxine

In suspected central hypothyroidism, ICI hypophysitis, or autoimmune polyglandular syndrome, starting LT4 accelerates cortisol metabolism and can precipitate adrenal crisis. Check morning cortisol / start glucocorticoids first.


subclinical hypothyroidism (SCH)

Elevated TSH with normal free T4 (confirm with repeat TSH + free T4 in 2–3 months, as mild elevations often normalise spontaneously). Anti-TPO antibodies help stratify progression risk (~4%/year if TPO+ vs ~2%/year if TPO−).

TSH & contextmanagementrationale
TSH >10 mU/Ltreat with LT4higher progression to overt disease, dyslipidaemia, and CV/HF risk
TSH 4.5–10 mU/L, age <65consider LT4 if clearly symptomatic, goitre, TPO+, or planning pregnancytrial 3–6 months; stop if symptoms do not improve
TSH 4.5–10 mU/L, age ≥65do not routinely treat (observe)TRUST (2017) (n = 737, ≥65 y, TSH 4.6–19.9) showed no improvement in hypothyroid symptoms or tiredness; overtreatment causes AF and bone loss
pregnancyspecific thresholds applysee thyroid disease in pregnancy

persistent TSH elevation on levothyroxine

When TSH stays high despite escalating LT4 doses (>1.6–2.0 µg/kg/day), check in order:

  1. Adherence (commonest cause — supervised weekly dosing or pill counts if suspected).
  2. Timing & absorption interference: take LT4 on an empty stomach 30–60 minutes before breakfast (or at bedtime ≥3 h after food) and separate by ≥4 hours from calcium, iron, bile acid sequestrants, sucralfate, phosphate binders, and antacids. PPIs, H. pylori gastritis, and coeliac disease impair gastric acid–dependent absorption.
  3. Increased clearance or TBG binding: oestrogen therapy (oral MHT/OCP increases TBG → higher LT4 need; transdermal oestrogen has minimal effect), rifampin, carbamazepine, phenytoin, phenobarbital, sertraline, tyrosine kinase inhibitors.
  4. Weight gain or formulation switching (keep brand consistent when TSH is tightly titrated).

Prepared 2026-11-19. Not yet verified — check every number against the sources.

Key references

+1 more source

Suggest a correction hypothyroidism